Dr Reddys Laboratories share price

Moderate risk
  • 24%Low risk
  • 24%Moderate risk
  • 24%Balanced risk
  • 24%High risk
  • 24%Extreme risk
  • ₹1,163.70(0.36%)
    April 17, 2025 15:53:45 PM IST
    • NSE
    • BSE
  • Vol : 2.83M (NSE + BSE)
    Last 20 day avg : 3.17 M

Dr Reddys Laboratories is trading 0.36% upper at Rs 1,163.70 as compared to its last closing price. Dr Reddys Laboratories has been trading in the price range of 1,173.20 & 1,150.00. Dr Reddys Laboratories has given -16.20% in this year & 5.02% in the last 5 days. Dr Reddys Laboratories has TTM P/E ratio 21.53 as compared to the sector P/E of 29.14.There are 34 analysts who have initiated coverage on Dr Reddys Laboratories. There are 6 analysts who have given it a strong buy rating & 8 analysts have given it a buy rating. 8 analysts have given the stock a sell rating.The company posted a net profit of 1,413.70 Crores in its last quarter.Listed peers of Dr Reddys Laboratories include Cipla (1.27%), Torrent Pharmaceuticals (1.03%), Dr Reddys Laboratories (0.36%).The Mutual Fund holding in Dr Reddys Laboratories was at 12.89% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Dr Reddys Laboratories was at 25.75% in 31 Mar 2025. The FII holding has decreased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Key Metrics

Updated on Apr 20, 2025, 04:21 PM UTC

  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.69
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.43
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    18.06
    Lower than historical values
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.31
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.07
    Higher than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
1,150.00
Highest
1,173.20
52 week range
Lowest
1,025.90
Highest
1,420.20
Dr Reddys Laboratories News
Dr Reddys Laboratories Financials
Financials
Financials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
View all
  • Income
  • Balance Sheet
  • Cash Flow
Loading...
Units in the chart are in crores
Insights
  • Financial
  • Valuation
    • financial-insightsCompany is profitable
    • financial-insightsThe company's revenue grew in December quarter by 15.81% from Rs 8381.20 crore to Rs 7236.80 crore, year-on-year
    • financial-insightsThe company has grown its December quarter profit by 2.38% from Rs 1380.90 crore to Rs 1413.70 crore, year-on-year
    • financial-insightsThe debt to equity of the company is higher than the industry median
    • financial-insightsCompany can comfortably pay off its interest obligations with its earnings
Dr Reddys Laboratories Technical Analysis
Pivot Level - classic
Info
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
  • R1
  • 1,238.67
  • R2
  • 1,333.28
  • R3
  • 1,439.67
Pivot1,132.28
  • S1
  • 1,037.67
  • S2
  • 931.28
  • S3
  • 836.67
Short Term
Info
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Info
Considers price movement over the last 6 months
Not Available
  • Very Bearish
  • Bearish
  • Neutral
  • Very Bullish
  • Bullish
Trends unavailable at the moment.
Dr Reddys Laboratories Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Cipla
Moderately Bullish
1,515.451.271,22,390.3428.184.580.860.84
Torrent Pharmaceuticals
Bullish
3,254.251.031,10,133.6668.7116.070.9824.33
Dr Reddys Laboratories
Neutral
1,163.700.3697,101.0317.613.430.692.12
Lupin
Bearish
1,934.50-0.0788,322.5142.706.180.411.09
Zydus Lifesciences
Bearish
831.401.1383,658.2921.934.220.360.13
Dr Reddys Laboratories Shareholding
View All
Shareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
    No Data
    Shareholding pattern for Dr Reddys Laboratories is currently unavailable
    Please check back later.
    Shareholding Insights
    • InsightsPromoter(s) does not have a high stake in the company
    • InsightsThere is no pledging of shares in promoter holding
    • InsightsFIIs are not invested in this company
    • InsightsMutual Funds are not invested in this company.
    Mutual Fund Ownership
    View all
    ICICI Prudential Nifty Pharma Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 7.45
    • % of AUM 9.23
    ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Growth
    NA
    • Amount Invested (Cr.) 439.67
    • % of AUM 8.95
    PGIM India Healthcare Fund Regular Growth
    NA
    • Amount Invested (Cr.) 6.29
    • % of AUM 6.03
    Bandhan BSE Healthcare Index Fund Regular Growth
    NA
    • Amount Invested (Cr.) 0.98
    • % of AUM 5.62
    Nippon India Pharma Fund - Growth
    NA
    • Amount Invested (Cr.) 419.03
    • % of AUM 5.19
    Dr Reddys Laboratories Corporate Actions
    View all
    • Board Meetings
    • AGM
    • Dividends
    • Bonus
    • Split
    • Rights
    Meeting DatePurpose
    2025-05-09Audited Results, Dividend & Others
    2025-01-23Quarterly Results
    2024-11-05Quarterly Results
    2024-07-27Quarterly Results & Stock Split
    2024-05-07Audited Results & Final Dividend
    About the company Dr Reddys Laboratories
    • IndustryBiotechnology & Drugs
    • ISININE089A01031
    • BSE Code500124
    • NSE CodeDRREDDY
    Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
    • Management Info
    • Kallam ReddyChairman of the Board
    • Gunupati PrasadCo-Chairman of the Board, Managing Director
    • Erez IsraeliChief Executive Officer
    • M. V. NarasimhamChief Financial Officer
    • Patrick AghanianChief Executive Officer, European Generics
    • Milan KalawadiaChief Executive Officer, North America
    • M. RamanaChief Executive Officer, Branded Markets (India and Emerging Countries)
    • Archana BhaskarChief Human Resource Officer
    • Phani Mitra B.Chief Information Officer
    • Sushrut KulkarniGlobal Head of Integrated Product Development Organisation
    Dr Reddys Laboratories Share Price FAQs

    Dr Reddys Laboratories is trading at 1163.70 as on Thu Apr 17 2025 10:23:45. This is 0.36% upper as compared to its previous closing price of 1159.50.

    The market capitalization of Dr Reddys Laboratories is 97101.03 Cr as on Thu Apr 17 2025 10:23:45.

    The average broker rating on Dr Reddys Laboratories is Hold. The breakup of analyst rating is given below -

    • 6 analysts have given a strong buy rating
    • 8 analysts have given a buy rating
    • 8 analysts have given a hold rating
    • 8 analysts have given a sell rating
    • 4 analysts have given a strong sell rating

    The 52 wk high for Dr Reddys Laboratories is 1420.20 whereas the 52 wk low is 1025.90

    Dr Reddys Laboratories can be analyzed on the following key metrics -

    • TTM P/E: 21.53
    • Sector P/E: 29.14
    • Dividend Yield: 0.69%
    • D/E ratio: -

    Dr Reddys Laboratories reported a net profit of 5577.90 Cr in 2024.

    The Mutual Fund Shareholding was 12.89% at the end of 31 Mar 2025.

    Quick Links
    EQUITY QUICK LINKS
    Dr Reddys Laboratories QUICK LINKS
    FROM MARKETS
    RELATED LINKS
    Quarterly Results
    Business News/Market/Market Stats/   Dr Reddys Laboratories share price

    Wait for it…

    Log in to our website to save your bookmarks. It'll just take a moment.